Bio-Rad Laboratories (NYSE:BIO) – Investment analysts at Jefferies Group boosted their Q2 2018 EPS estimates for Bio-Rad Laboratories in a report issued on Monday, April 16th. Jefferies Group analyst B. Couillard now anticipates that the medical research company will earn $1.17 per share for the quarter, up from their previous estimate of $0.93. Jefferies Group currently has a “Buy” rating and a $325.00 target price on the stock. Jefferies Group also issued estimates for Bio-Rad Laboratories’ Q3 2018 earnings at $1.33 EPS.
Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Tuesday, February 27th. The medical research company reported $1.50 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.28 by $0.22. The company had revenue of $620.43 million for the quarter, compared to analysts’ expectations of $618.89 million. Bio-Rad Laboratories had a net margin of 5.31% and a return on equity of 3.63%.
Shares of Bio-Rad Laboratories stock opened at $264.19 on Wednesday. The firm has a market cap of $7,801.77, a PE ratio of 64.44, a price-to-earnings-growth ratio of 3.05 and a beta of 0.94. Bio-Rad Laboratories has a 1-year low of $205.83 and a 1-year high of $279.59. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.75 and a current ratio of 3.93.
Institutional investors have recently modified their holdings of the company. Tower Research Capital LLC TRC boosted its stake in shares of Bio-Rad Laboratories by 297.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 560 shares of the medical research company’s stock worth $134,000 after acquiring an additional 419 shares during the last quarter. Private Advisor Group LLC purchased a new position in shares of Bio-Rad Laboratories during the 4th quarter valued at $248,000. Macquarie Group Ltd. purchased a new position in shares of Bio-Rad Laboratories during the 3rd quarter valued at $255,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Bio-Rad Laboratories by 42.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,165 shares of the medical research company’s stock valued at $278,000 after buying an additional 350 shares in the last quarter. Finally, Advisory Services Network LLC lifted its stake in shares of Bio-Rad Laboratories by 218.6% during the 4th quarter. Advisory Services Network LLC now owns 1,217 shares of the medical research company’s stock valued at $290,000 after buying an additional 835 shares in the last quarter. Institutional investors and hedge funds own 64.52% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://weekherald.com/2018/04/19/q2-2018-earnings-forecast-for-bio-rad-laboratories-bio-issued-by-jefferies-group.html.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.